125 related articles for article (PubMed ID: 34738499)
1. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21).
Mennitto A; Zattarin E; Di Maio M; Bimbatti D; De Giorgi U; Buti S; Santini D; Casadei C; Sorarù M; Messina C; Mucciarini C; Di Lorenzo G; Roviello G; Buttigliero C; Stellato M; Sepe P; Claps M; Guadalupi V; Ottini A; Pignata S; De Braud FG; Verzoni E; Procopio G
Expert Rev Anticancer Ther; 2022 Jan; 22(1):115-121. PubMed ID: 34738499
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9).
Damassi A; Cremante M; Signori A; Rebuzzi SE; Fornarini G; Giudice GC; Maruzzo M; Procopio G; Sorarù M; Di Napoli M; Fratino L; Santini D; Grillone F; Ballestrin M; Dionese M; Nasso C; Catalano F; Murianni V; Rescigno P; Anpalakhan S; Banna GL; Basso U; Buti S
Clin Genitourin Cancer; 2024 Apr; 22(2):126-133.e2. PubMed ID: 37932204
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
Martínez Chanzá N; Xie W; Asim Bilen M; Dzimitrowicz H; Burkart J; Geynisman DM; Balakrishnan A; Bowman IA; Jain R; Stadler W; Zakharia Y; Narayan V; Beuselinck B; McKay RR; Tripathi A; Pachynski R; Hahn AW; Hsu J; Shah SA; Lam ET; Rose TL; Mega AE; Vogelzang N; Harrison MR; Mortazavi A; Plimack ER; Vaishampayan U; Hammers H; George S; Haas N; Agarwal N; Pal SK; Srinivas S; Carneiro BA; Heng DYC; Bosse D; Choueiri TK; Harshman LC
Lancet Oncol; 2019 Apr; 20(4):581-590. PubMed ID: 30827746
[TBL] [Abstract][Full Text] [Related]
4. Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma.
Bruchbacher A; Franke J; Alimohammadi A; Laukhtina E; Fajkovic H; Schmidinger M
Clin Genitourin Cancer; 2024 Apr; 22(2):98-108. PubMed ID: 37926597
[TBL] [Abstract][Full Text] [Related]
5. Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma.
Sato R; Matsushita Y; Takemura A; Sugiyama M; Watanabe K; Watanabe H; Tamura K; Motoyama D; Nagata M; Otsuka A; Furuse H; Miyake H
Anticancer Res; 2024 Feb; 44(2):781-786. PubMed ID: 38307571
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence.
Gross-Goupil M; Bodnar L; Campbell MT; Michael A; Venugopal B; Żołnierek J; Dutailly P; Procopio G; Albiges L
Clin Genitourin Cancer; 2024 Feb; 22(1):84-97. PubMed ID: 38101983
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis.
Schmidt E; Lister J; Neumann M; Wiecek W; Fu S; Vataire AL; Sostar J; Huang S; Marteau F
Target Oncol; 2018 Apr; 13(2):205-216. PubMed ID: 29492762
[TBL] [Abstract][Full Text] [Related]
8. Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.
Blanchet B; Xu-Vuilard A; Jouinot A; Puisset F; Combarel D; Huillard O; Le Louedec F; Thomas F; Teixeira M; Flippot R; Mourey L; Albiges L; Pudlarz T; Joly C; Tournigand C; Chauvin J; Puszkiel A; Chatelut E; Decleves X; Vidal M; Goldwasser F; Oudard S; Medioni J; Vano YA
Br J Cancer; 2024 Apr; 130(6):961-969. PubMed ID: 38272963
[TBL] [Abstract][Full Text] [Related]
9. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
Hahn AW; Surasi DS; Viscuse PV; Bathala TK; Wiele AJ; Campbell MT; Zurita AJ; Shah AY; Jonasch E; Gao J; Goswami S; Alhalabi O; Rao P; Sircar K; Tannir NM; Msaouel P
Oncologist; 2024 May; 29(5):392-399. PubMed ID: 38035767
[TBL] [Abstract][Full Text] [Related]
10. Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma.
Borkowetz A; Sommer U; Baretton G; Gruellich C; Bürk BT; Erb HHH; Thomas C;
World J Urol; 2024 Feb; 42(1):94. PubMed ID: 38386122
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study.
Sazuka T; Matsushita Y; Sato H; Osawa T; Hinata N; Hatakeyama S; Numakura K; Ueda K; Kimura T; Takahashi M; Tanaka H; Kawasaki Y; Kurahashi T; Kato T; Fujita K; Miyake M; Kojima T; Kitamura H; Miyake H; Ichikawa T
Sci Rep; 2023 Nov; 13(1):20629. PubMed ID: 37996622
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric study.
Baudry E; Naoun N; Auclin E; Saldana C; Barthelemy P; Geoffrois L; Thibault C; de Vries-Brilland M; Borchiellini D; Maillet D; Hirsch L; Vauchier C; Carril-Ajuria L; Colomba E; Bernard-Tessier A; Escudier B; Flippot R; Albigès L
Eur J Cancer; 2023 Nov; 193():113292. PubMed ID: 37717282
[TBL] [Abstract][Full Text] [Related]
13. Activity of cabozantinib in further line treatment of metastatic clear cell renal cell carcinoma. Real-world experience in a single-center retrospective study.
Domański P; Jarosińska J; Kruczyk B; Piętak M; Mydlak A; Demkow T; Kuncman Ł; Darewicz M; Sikora-Kupis B; Dumnicka P; Kucharz J
Contemp Oncol (Pozn); 2023; 27(3):190-197. PubMed ID: 38239858
[TBL] [Abstract][Full Text] [Related]
14. [Multicentric Hungarian results of cabozantinib therapy in patients with metastatic kidney cancer based on real-world data].
Maráz A; Nagyiványi K; Balogh I; Bodoky G; Mangel L; Küronya Z; Géczi L; Torday L; Dudás S; Szűcs M; Nagy Z; Hornyák L; Zolcsák Z; Bassam A; Kocsis J; Keresztes T; Kullmann T; Máhr K; Solymosi T; Papdán T; Szabó I; Varga Z; Biró K
Magy Onkol; 2023 Mar; 67(1):1-10. PubMed ID: 36989491
[TBL] [Abstract][Full Text] [Related]
15. Extended disease control with unconventional cabozantinib dose increase in metastatic renal cell carcinoma.
Sharma A; Elias R; Christie A; Williams NS; Pedrosa I; Bjarnason GA; Brugarolas J
Kidney Cancer; 2022; 6(1):69-79. PubMed ID: 36743424
[TBL] [Abstract][Full Text] [Related]
16. Erratum to: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma.
Sharma A; Elias R; Christie A; Williams NS; Pedrosa I; Bjarnason GA; Brugarolas J
Kidney Cancer; 2023; 7(1):15. PubMed ID: 36999139
[TBL] [Abstract][Full Text] [Related]
17. First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
Vano YA; Ladoire S; Elaidi R; Dermeche S; Eymard JC; Falkowski S; Gross-Goupil M; Malouf G; Narciso B; Sajous C; Tartas S; Voog E; Ravaud A
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771710
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma.
Meza L; Malhotra J; Favorito C; Pal SK
Future Oncol; 2022 Jan; 18(1):21-33. PubMed ID: 34766841
[TBL] [Abstract][Full Text] [Related]
19. Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib.
Scirocchi F; Napoletano C; Pace A; Rahimi Koshkaki H; Di Filippo A; Zizzari IG; Nuti M; Rughetti A
Front Oncol; 2021; 11():755433. PubMed ID: 34745989
[TBL] [Abstract][Full Text] [Related]
20. Targeting c-Met to Improve Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma.
Lindner AK; Pichler M; Thurnher M; Pichler R
Eur Urol; 2022 Jan; 81(1):1-2. PubMed ID: 34794854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
